Appendix 4C - Quarterly Cash Flow Report - March 2018


Sienna is pleased to release its Appendix 4C – Quarterly Cash Flow Report for the quarter ending 31 March 2018.

The Company ended the quarter with a cash balance of $2.9 million. Product orders were received in each month of the quarter. An inter-bank communication problem prevented the receipt of funds for our US distributor’s (StatLab) January order during the quarter. The issue was resolved and the funds were received in early April. Payments for the February and March orders are due to be received in the quarter ending 30 June 2018.

Following the lodgement of its 2017 R&D Tax Incentive application, Sienna expects to receive the R&D tax refund in the quarter ending June 2018.

StatLab no longer sells to Bostwick Laboratories as a result of the acquisition of Bostwick by Poplar Healthcare and the closing of Bostwick’s New York operations. Sienna expects that all future USA-based revenues will be generated through laboratories engaged and established as customers of StatLab, including Poplar Healthcare.

During the quarter, Sienna continued to progress the Company’s strategic growth initiatives, including the additional application and geographical expansion programs for the in-vitro diagnostic test for hTERT. Considerable work has also been carried out in pursuit of the product pipeline expansion program.

Download Appendix 4C - March 2018


No Very

Captcha Image

Sign up for updates